Sugi Predict

Sugi Predict / Compounds / SCHEMBL721054

SCHEMBL721054

SCHEMBL721054

COc1cc(NC(C)=O)ccc1C(=O)NO

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 0.57
▸ TDP1 Q9NUW8 1/20 0.54
▸ SMN1; SMN2 Q16637 3/20 0.53
▸ ALDH1A1 P00352 4/20 0.52
▸ NPC1 O15118 3/20 0.50
▸ RAB9A P51151 3/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ MAPT P10636 3/20 0.49
▸ POLB P06746 1/20 0.49
▸ HTT P42858 3/20 0.48
▸ LMNA P02545 1/20 0.48
▸ ALOX15 P16050 1/20 0.48
▸ KCNK3 O14649 1/20 0.48
▸ KCNK9 Q9NPC2 1/20 0.48
▸ NFKB1 P19838 1/20 0.47
▸ NFKB2 Q00653 1/20 0.47
▸ RELA Q04206 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10033006 0.88 ALDH1A1 (0.63) MAPK1SMN1; SMN2ALDH1A1KMT2AMAPT
SCHEMBL1493992 0.85 MAPK1 (0.57) MAPK1TDP1SMN1; SMN2ALDH1A1NPC1
SCHEMBL1162352 0.84 TDP1 (0.56) MAPK1TDP1SMN1; SMN2ALDH1A1KMT2A
SCHEMBL2555975 0.84 TDP1 (0.73) MAPK1TDP1SMN1; SMN2ALDH1A1KMT2A
SCHEMBL14421098 0.83 TDP1 (0.55) MAPK1TDP1SMN1; SMN2ALDH1A1NPC1
SCHEMBL12970763 0.83 TDP1 (0.55) MAPK1TDP1SMN1; SMN2ALDH1A1NPC1
SCHEMBL13697401 0.80 TDP1 (0.52) MAPK1TDP1SMN1; SMN2ALDH1A1KMT2A
SCHEMBL30492996 0.80 SMN1; SMN2 (0.68) MAPK1SMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL1851780 0.80 SMN1; SMN2 (0.68) MAPK1SMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL5208087 0.79 TDP1 (0.55) MAPK1TDP1SMN1; SMN2ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260115159-A1 ALKYLAMIDO COMPOUNDS AND USES THEREOF NOGRA PHARMA LTD (IE) 2026-04-30 — — US disclosed
US-12291494-B2 Methods of treating fibrosis NOGRA PHARMA LIMITED (IE) 2025-05-06 — — US disclosed
US-20240279157-A1 METHODS OF TREATING FIBROSIS NOGRA PHARMA LIMITED (IE) 2024-08-22 — — US disclosed
US-11753365-B2 Methods of treating fibrosis NOGRA PHARMA LIMITED (IE) 2023-09-12 — — US disclosed
US-11753365-B2 Methods of treating fibrosis NOGRA PHARMA LIMITED (IE) 2023-09-12 — — US disclosed
US-11753365-B2 Methods of treating fibrosis NOGRA PHARMA LIMITED (IE) 2023-09-12 — — US disclosed
CN-116602950-A Methods of treating fibrosis 诺格拉制药有限公司 2023-08-18 — — CN disclosed
US-20220354809-A1 Alkylamido Compounds and Uses Thereof NOGRA PHARMA LIMITED (IE) 2022-11-10 — — US disclosed
US-20220354809-A1 Alkylamido Compounds and Uses Thereof NOGRA PHARMA LIMITED (IE) 2022-11-10 — — US disclosed
US-20220033346-A1 METHODS OF TREATING FIBROSIS NOGRA PHARMA LIMITED (IE) 2022-02-03 — — US disclosed
US-20120053245-A1 Methods of Treating Hair Related Conditions GIULIANI INTERNATIONAL, LTD. (IE) 2012-03-01 — — US disclosed
US-20120053245-A1 Methods of Treating Hair Related Conditions GIULIANI INTERNATIONAL, LTD. (IE) 2012-03-01 — — US disclosed
US-20120053244-A1 Alkylamido Compounds and Uses Thereof NOGRA PHARMA LIMITED (IE) 2012-03-01 — — US disclosed
US-20120053244-A1 Alkylamido Compounds and Uses Thereof NOGRA PHARMA LIMITED (IE) 2012-03-01 — — US disclosed
EP-2396081-A2 ALKYLAMIDO COMPOUNDS AND USES THEREOF Giuliani International Limited (IE) 2011-12-21 — — EP disclosed
EP-2396082-A2 METHODS FOR TREATING HAIR RELATED CONDITIONS Giuliani International Limited (IE) 2011-12-21 — — EP disclosed
WO-2010091892-A2 ALKYLAMIDO COMPOUNDS AND USES THEREOF GIULIANI INTERNATIONAL LIMITED (IE) 2010-08-19 — — WO disclosed
WO-2010091892-A2 ALKYLAMIDO COMPOUNDS AND USES THEREOF GIULIANI INTERNATIONAL LIMITED (IE) 2010-08-19 — — WO disclosed
WO-2010091894-A2 METHODS OF TREATING HAIR RELATED CONDITIONS GIULIANI INTERNATIONAL LIMITED (IE) 2010-08-19 — — WO disclosed
WO-2010091894-A2 METHODS OF TREATING HAIR RELATED CONDITIONS GIULIANI INTERNATIONAL LIMITED (IE) 2010-08-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220354809-A1 Alkylamido Compounds and Uses Thereof EGFR, PPARG, ERBB3 MAPK1 1192/4885TDP1 3825/4885SMN1; SMN2 4752/4885
US-11753365-B2 Methods of treating fibrosis MMP1, MMP8, FABP2 MAPK1 4456/4885TDP1 4088/4885SMN1; SMN2 3152/4885
US-20120053245-A1 Methods of Treating Hair Related Conditions PPARA, PPARG, PPARD MAPK1 3982/4885TDP1 3941/4885SMN1; SMN2 4815/4885
US-20240279157-A1 METHODS OF TREATING FIBROSIS MMP1, MMP8, FABP2 MAPK1 4456/4885TDP1 4088/4885SMN1; SMN2 3152/4885
US-20260115159-A1 ALKYLAMIDO COMPOUNDS AND USES THEREOF EGFR, PPARD, PPARG MAPK1 491/4885TDP1 4623/4885SMN1; SMN2 4574/4885
US-20120053244-A1 Alkylamido Compounds and Uses Thereof EGFR, PPARG, ERBB3 MAPK1 1192/4885TDP1 3825/4885SMN1; SMN2 4752/4885
US-12291494-B2 Methods of treating fibrosis MMP1, MMP8, FABP2 MAPK1 4456/4885TDP1 4088/4885SMN1; SMN2 3152/4885
US-20220033346-A1 METHODS OF TREATING FIBROSIS MMP1, MMP8, FABP2 MAPK1 4456/4885TDP1 4088/4885SMN1; SMN2 3152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.